Zimmer Biomet Holdings Inc.'s meniscal repair device JuggerStitch was approved in the U.S. under the Food and Drug Administration's 510(k) regulatory pathway.
The device is meant to treat a meniscus tear in the knee via keyhole surgery. Compared to traditional surgery techniques, JuggerStitch offers a lesser invasive method of treatment.
JuggerStitch features two soft anchors connected by a knotless, self-locking suture loop for better tissue preservation and improved surgeon's control of the tissue compression at the repair site, the company said in a press release.
Zimmer Biomet designs and markets musculoskeletal healthcare products for the U.S. and international markets.
